Treatment Algorithms for Early-Stage HR+ Breast Cancer

Opinion
Video

Virginia Kaklamani, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss treatment paradigms for patients with early-stage HR+ breast cancer, highlighting the differences in treatment for premenopausal and postmenopausal patients.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content
Health-Related Quality of Life Complimented Efficacy/Safety With T-DXd in Breast Cancer

Health-Related Quality of Life Complimented Efficacy/Safety With T-DXd in Breast Cancer

Kyle Doherty
December 13th 2024
Article
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

Niraparib/Dostarlimab Shows Promise in BRCA+ ER+/HER2– Breast Cancer

Ariana Pelosci
December 13th 2024
Article

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Ribociclib and Endocrine Therapy Show Favorable PFS Trend in Breast Cancer

Ribociclib and Endocrine Therapy Show Favorable PFS Trend in Breast Cancer

Darlene Dobkowski, MA
December 13th 2024
Article

Data from the RIGHT Choice study showed that ribociclib/ET yielded efficacy benefits for luminal B/HER2E breast cancer vs combination chemotherapy.

Palbociclib/ET/anti-HER2 Therapy Demonstrates Clinical Benefit in Breast Cancer

Palbociclib/ET/anti-HER2 Therapy Demonstrates Clinical Benefit in Breast Cancer

Dylann Cohn-Emery
December 13th 2024
Article

Palbociclib combination therapy elicited a progression-free survival of 44.3 months compared with the 29.1 months of SOC in HR+, HER2+ breast cancer.